Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation
Paula Fernández‐Palanca, Tania Payo‐Serafín, Beatriz San‐Miguel, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 5, pp. 1066-1082
Open Access | Times Cited: 18

Showing 18 citing articles:

The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
Kyoko Oura, Asahiro Morishita, Sae Hamaya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2805-2805
Open Access | Times Cited: 25
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Y. Qin, Shisong Han, Yahan Yu, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1808-1831
Closed Access | Times Cited: 10
Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells
ZhaoLi Wu, Jia Wang
Discovery Medicine (2024) Vol. 36, Iss. 180, pp. 199-199
Open Access | Times Cited: 8
Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments
Konstantinos Avgoustakis, Athina Angelopoulou
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 179-179
Open Access | Times Cited: 6
HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation
Shuai Yan, Lu Chen, Hao Zhuang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 8, pp. 3046-3060
Open Access | Times Cited: 6
Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma
Danyan Gu, Meng Tong, Jing Wang, et al.
Discover Oncology (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
Worse survival of hepatocellular cancer patients with membranous insulin receptor overexpression
S. Heckl, Carolin Schneider, Lukas Kercher, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
LCAT Deficiency Promotes Hepatocellular Carcinoma Progression and Lenvatinib Resistance by Promoting Triglyceride Catabolism and Fatty Acid Oxidation
Min Xu, Peiyi Xie, Shaoqing Liu, et al.
Cancer Letters (2025), pp. 217469-217469
Closed Access
Tyrosine Kinase Inhibitor Lenvatinib Based Nano Formulations and Cutting-Edge Scale-Up Technologies in revolutionizing Cancer Therapy
Samia Shaikh, Padakanti Sandeep Chary, Neelesh Kumar Mehra
ACS Applied Bio Materials (2025) Vol. 8, Iss. 3, pp. 1749-1784
Closed Access
Vascular endothelial growth factor released from lenvatinib‐resistant hepatocellular carcinoma promotes malignant behavior and drug resistance through tumor‐associated macrophages
Yukako Takehara, Yuhei Waki, Yuji Morine, et al.
Hepatology Research (2025)
Closed Access
Lenvatinib inhibited HCC cell migration and invasion through regulating the transcription and ubiquitination of UHRF1 and DNMT1
Ting Fang, Zhen Jiao, Yuting You, et al.
Biochemical Pharmacology (2023) Vol. 210, pp. 115489-115489
Closed Access | Times Cited: 12
circFAM134B is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma
Tao Bi, Qianqian Lu, Xiaohong Pan, et al.
Cell Cycle (2023) Vol. 22, Iss. 17, pp. 1900-1920
Open Access | Times Cited: 7
HIF-1α-activated TMEM237 promotes hepatocellular carcinoma progression via the NPHP1/Pyk2/ERK pathway
Tianxiang Chen, Liang Wang, Chao Chen, et al.
Cellular and Molecular Life Sciences (2023) Vol. 80, Iss. 5
Open Access | Times Cited: 6
“Quinoline Analogues and Nanocarrier Systems: A Dual Approach to Anti-Tubercular Therapy"
Satendra Kumar, Niranjan Kaushik, Jagdish K. Sahu, et al.
European Journal of Medicinal Chemistry Reports (2024) Vol. 12, pp. 100212-100212
Open Access | Times Cited: 1
Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer
Rehab Hegazy, Drishti Rathod, Aishwarya Saraswat, et al.
Journal of Molecular Liquids (2024) Vol. 398, pp. 124263-124263
Closed Access
Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review)
Ganghui Ye, Meng Ye, Shengkan Jin
American Journal of Cancer Research (2024) Vol. 14, Iss. 9, pp. 4113-4171
Closed Access
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Yuhang Chen, Shengyuan Dai, Chien‐shan Cheng, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access
Latest Research Progress on the Mechanisms of Lenvatinib Resistance
Qi Ding, Yusen Wu, Yong Li
Journal of Biosciences and Medicines (2024) Vol. 12, Iss. 12, pp. 424-437
Open Access
Page 1

Scroll to top